• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Infectives Partnering Terms and Agreements Product Image

Infectives Partnering Terms and Agreements

  • ID: 2190608
  • August 2014
  • Region: Global
  • 803 pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter infectives partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors infectives technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,000 links to online copies of actual infectives deals and contract documents as submitted to the Securities READ MORE >

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectives dealmaking

2.1. Introduction
2.2. Infectives partnering over the years
2.3. Bigpharma infectives dealmaking activity
2.4. Bigpharma not active in infectives
2.5. Infectives partnering by deal type
2.6. Infectives partnering by industry sector
2.7. Infectives partnering by stage of development
2.8. Infectives partnering by technology type
2.9. Infectives partnering by infectives indication
2.10. Average deal terms for infectives
2.10.1 Infectives headline values
2.10.2 Infectives upfront payments
2.10.3 Infectives milestone payments
2.10.4 Infectives royalty rates
Chapter 3 – Leading infectives deals

3.1. Introduction
3.2. Top infectives deals by value
3.3. Top infectives deals involving bigpharma
Chapter 4 – Bigpharma infectives deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma infectives partnering company profiles

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB
Valeant
Warner Chilcott
Watson
Chapter 5 – Infectives partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Sub-license
Supply
Technology transfer
Termination
Warranty
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.4. By technology type
Adjuvant
Animal models
Antibodies
Monoclonal antibodies
Humanized mAb
Human mAb
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Equipment
Facilities
Genomics
Industrial chemicals
Natural product
Oligonucleotide
Orphan drug
Packaging
Pediatrics
Peptides
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Vaccines
5.5. By therapeutic indication
Infectives
Bacterial
Anthrax
Escherichia Coli (E-coli)
Haemophilus influenzae type b (Hib)
Methicillin-resistant Staphylococcus aureus (MRSA)
Pertussis (Whooping Cough)
Pseudomonas aeruginosa
Sepsis
Tuberculosis (TB)
Fungal
Onychomycosis (Nail infection)
Parasitic
Tropical
Dengue fever
Malaria
Viral
Common cold
Ebola
Foot and mouth disease
Hepatitis A
Hepatitis B
Hepatitis C
Herpes simplex
HIV
Influenza
H5N1 (Avian Flu)
Japanese encephalitis
Respiratory syncytial virus (RSV)
Chapter 6 – Infectives dealmaking by indication

6.1. Introduction
6.2. Deals by therapeutic indication
Infectives
Bacterial
Anthrax
Campylobacter Jejuni
Clostridium difficile
Diphtheria
Escherichia Coli (E-coli)
Group A Streptococcus
Group B Streptococcus
Haemophilus influenzae type b (Hib)
Helicobacter Pylori
Lyme disease
Methicillin-resistant Staphylococcus aureus (MRSA)
Mycobacterium avium
Pertussis (Whooping Cough)
Pseudomonas aeruginosa
Salmonella
Sepsis
Tetanus
Tuberculosis (TB)
Fungal
Nail Psoriasis
Onychomycosis (Nail infection)
Parasitic
Tropical
African trypanosomiasis (Sleeping sickness)
Dengue fever
Malaria
Yellow fever
Viral
Common cold
Cytomegalovirus
Ebola
FIV
Foot and mouth disease
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Herpes simplex
HIV
Influenza
H1N1 (Swine Flu)
H5N1 (Avian Flu)
Japanese encephalitis
Polio
Respiratory syncytial virus (RSV)
Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Appendix

Appendix 1 – Directory of infectives deals by company A-Z 2009-2014
Appendix 2 – Directory of infectives deals by deal type 2009-2014
Appendix 3 – Directory of infectives deals by stage of development 2009-2014
Appendix 4 – Directory of infectives deals by technology type 2009-2014
Appendix 5 – Deal type definitions
Table of figures

Figure 1: Infectives partnering since 2009
Figure 2: Bigpharma – top 50 – infectives deals 2009 to 2012
Figure 3: Bigpharma infectives deal frequency – 2009 to 2012
Figure 4: Inactive bigpharma in infectives 2009-2014
Figure 5: Infectives partnering by deal type since 2009
Figure 6: Infectives partnering by industry sector since 2009
Figure 7: Infectives partnering by stage of development since 2009
Figure 8: Infectives partnering by technology type since 2009
Figure 9: Infectives partnering by infective target since 2009
Figure 10: Infectives deals with a headline value
Figure 11: Infectives deal headline value distribution, US$million – discovery stage
Figure 12: Infectives deal headline value distribution, US$million – preclinical stage
Figure 13: Infectives deal headline value distribution, US$million – phase I stage
Figure 14: Infectives deal headline value distribution, US$million – phase II stage
Figure 15: Infectives deal headline value distribution, US$million – phase III stage
Figure 16: Infectives deal headline value distribution, US$million – regulatory stage
Figure 17: Infectives deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2005-2014
Figure 19: Infectives deals with upfront payment values
Figure 20: Infectives deal upfront payment distribution, US$million – discovery stage
Figure 21: Infectives deal upfront payment distribution, US$million – preclinical stage
Figure 22: Infectives deal upfront payment distribution, US$million – phase I stage
Figure 23: Infectives deal upfront payment distribution, US$million – phase II stage
Figure 24: Infectives deal upfront payment distribution, US$million – phase III stage
Figure 25: Infectives deal upfront payment distribution, US$million – regulatory stage
Figure 26: Infectives deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2005-2014
Figure 28: Infectives deals with milestone payments
Figure 29: Infectives deal milestone distribution, US$million – discovery stage
Figure 30: Infectives deal milestone distribution, US$million – preclinical stage
Figure 31: Infectives deal milestone distribution, US$million – phase I stage
Figure 32: Infectives deal milestone distribution, US$million – phase II stage
Figure 33: Infectives deal milestone distribution, US$million – phase III stage
Figure 34: Infectives deal milestone distribution, US$million – regulatory stage
Figure 35: Infectives deal milestone distribution, US$million – marketed stage
Figure 36: Infectives deals with royalty rates, %
Figure 37: Infectives deal royalty rate distribution, US$million – discovery stage
Figure 38: Infectives deal royalty rate distribution, US$million – preclinical stage
Figure 39: Infectives deal royalty rate distribution, US$million – phase I stage
Figure 40: Infectives deal royalty rate distribution, US$million – phase II stage
Figure 41: Infectives deal royalty rate distribution, US$million – phase III stage
Figure 42: Infectives deal royalty rate distribution, US$million – regulatory stage
Figure 43: Infectives deal royalty rate distribution, US$million – marketed stage
Figure 44: Summary median royalty rate by stage of development, 2005-2014
Figure 45: Top infectives deals by value since 2009
Figure 46: Top infectives deals signed by bigpharma value since 2005
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos